Cognition Therapeutics Initiates Patient Dosing in Phase 2 SHINE Study of Elayta™ in Patients with Mild-to-Moderate Alzheimer's Disease
November 08, 2018 08:03 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic protection and restoration in Alzheimer’s disease and other...
Cognition Therapeutics Initiates NIA-Funded SNAP Study of Elayta™ to Measure Toxic Oligomer Displacement and Clearance in Alzheimer's Disease
June 05, 2018 08:02 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, June 05, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at the Annual ASENT Meeting
March 06, 2018 14:04 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, March 06, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
Cognition Therapeutics to Participate in Leerink Partners 7th Annual Global Healthcare Conference
February 12, 2018 09:00 ET
|
Cognition Therapeutics, Inc.
PITTSBURGH, Feb. 12, 2018 (GLOBE NEWSWIRE) --
Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment...
Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at Sachs Neuroscience Innovation Forum
January 04, 2018 08:05 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
Cognition Therapeutics’ Alzheimer’s Disease Candidate CT1812 Meets Phase 1b/2a Study Objectives: Well Tolerated with Positive Influence on Biomarkers of Synapse Recovery
November 04, 2017 10:45 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Nov. 04, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
Function of Cognition Therapeutics’ Neurological Drug Screening Platform Presented at American Chemical Society National Meeting
August 23, 2017 09:45 ET
|
Cognition Therapeutics, Inc.
PITTSBURGH, Aug. 23, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
Cognition Therapeutics CEO Kenneth I. Moch to Present at Canaccord Genuity Annual Growth Conference
July 31, 2017 08:30 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, July 31, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
Cognition Therapeutics Reports Drug-Drug Interaction Results for CT1812, a Disease-Modifying Alzheimer’s Disease Candidate
July 19, 2017 04:35 ET
|
Cognition Therapeutics, Inc.
PITTSBURGH, July 19, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative small molecule therapeutics for the...